Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Here are the HIV treatment news stories with the most views this year.
One avenue in the HIV cure research field involves using agents that prevent reactivation of HIV replication in latently infected cells.
Researchers believe that macrophage cells in the liver that harbor such inert HIV are not a part of the viral reservoir.
As a result, cure treatments may have to approach these two targets differently.
The latest collection of articles stems from a tiny study in Uganda, neither peer-reviewed nor presented at a conference.
Post-HIV-treatment viral control is more likely in those treated very early.
A new study analyzes nuances in a cohort of six people who also received stem cell transplants for blood cancers.
An antibody treatment plus an immune-stimulating agent delayed viral rebound in primates infected with HIV-like virus.
Scientists have discovered a swifter and more precise way to edit the genome of immune cells, opening doors for cancer and HIV therapies.
Researchers drew immune cells from people on effective HIV treatment, cultured the cells and reinfused 40 million of them.
Such latently infected cells remain under the radar of antiretroviral treatment, which only works on replicating cells.
Today, with better understanding of the complex task at hand, cure researchers are investigating multiple avenues and taking the long view.
This is according to an analysis of pooled data from various studies looking at those who controlled HIV after stopping treatment.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
The “kick-and-kill” strategy—waking up latently infected immune cells so as to kill them—did not reduce participants’ viral DNA.
This disappointment highlights the challenge of translating animal research into human trials.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.